Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine if Irbesartan compared to Placebo would reduce the
risk of vascular events such as heart attack, stroke, non-cerebral thromboembolic event and
death in patients with Atrial Fibrillation (AF) and with at least one major risk of vascular
events.